Oyster Point Pharma, Inc. Deferred Tax Assets, Net of Valuation Allowance
Oyster Point Pharma, Inc. had Deferred Tax Assets, Net of Valuation Allowance of $1.57 million as of 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2022-02-24
- 2021-12-31: Deferred Tax Assets, Net of Valuation Allowance $1.57M.
- 2020-12-31: Deferred Tax Assets, Net of Valuation Allowance $1.01M.
- 2019-12-31: Deferred Tax Assets, Net of Valuation Allowance $932.00K.
- 2018-12-31: Deferred Tax Assets, Net of Valuation Allowance $64.00K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2021-12-31 | $1.57M 10-K · filed 2022-02-24 |
| 2020-12-31 | $1.01M 10-K · filed 2022-02-24 |
| 2019-12-31 | $932.00K 10-K · filed 2021-02-18 |
| 2018-12-31 | $64.00K 10-K · filed 2020-02-27 |